MICHAEL JAY YELLIN
Medical Practice in Montclair, NJ

2008005, Feb 28, 2008

Jan 25, 2007

11/698692

Michael Yellin - Montclair NJ, US
Leonard Chess - Scarsdale NY, US
David Thomas - Wellesley MA, US

A61K 39/395, A61P 1/02

424133100, 424141100

Activation of smooth muscle cells bearing CD40 on their cell surface by CD40 ligand is inhibited by contacting the smooth muscle cells with an anti-T-BAM (CD40L) antibody capable of inhibiting the interactions between CD40 ligand and the CD40-bearing smooth muscle cells, in an amount effective to inhibit activation of the smooth muscle cells. Activation of smooth muscle cells bearing CD40 on their surface by CD40 ligand in a subject is inhibited by administering to the subject an anti-T-BAM (CD40L) antibody capable of inhibiting the interaction between CD40 ligand and the smooth muscle cells, in an amount effective to inhibit activation of the cells. Conditions dependent on CD40 ligand-induced activation of CD40-bearing cells smooth muscle cells are treated, in particular inflammatory bowel disease.

2003021, Nov 27, 2003

Nov 15, 2002

10/298508

Michael Yellin - Montclair NJ, US
Leonard Chess - Scarsdale NY, US
David Thomas - Wellesley MA, US

A61K039/395

424/144100

Activation of smooth muscle cells bearing CD40 on their cell surface by CD40 ligand is inhibited by contacting the smooth muscle cells with an anti-T-BAM (CD40L) antibody capable of inhibiting the interactions between CD40 ligand and the CD40-bearing smooth muscle cells, in an amount effective to inhibit activation of the smooth muscle cells. Activation of smooth muscle cells bearing CD40 on their surface by CD40 ligand in a subject is inhibited by administering to the subject an anti-T-BAM (CD40L) antibody capable of inhibiting the interaction between CD40 ligand and the smooth muscle cells, in an amount effective to inhibit activation of the cells. Conditions dependent on CD40 ligand-induced activation of CD40-bearing cells smooth muscle cells are treated, in particular inflammatory bowel disease.

2005011, Jun 2, 2005

Jul 11, 2003

10/618298

Michael Yellin - Montclair NJ, US
Seth Lederman - New York NY, US
Leonard Chess - Scarsdale NY, US
David Thomas - Wellesley MA, US

A61K039/395

424141100, 424144100

Activation of cells bearing CD40 on their cell surface by CD40 ligand is inhibited by contacting the cells with an agent capable of inhibiting interaction between CD40 ligand and the cells, in an amount effective to inhibit activation of the cells. Activation of cells bearing CD40 on their surface by CD40 ligand in a subject is inhibited by administering to the subject an agent capable of inhibiting interaction between CD40 ligand and the cells, in an amount effective to inhibit activation of the cells. Conditions dependent on CD4O ligand-induced activation of CD40-bearing cells are treated.

2006005, Mar 16, 2006

Aug 31, 2005

11/218284

Geoffrey Nichol - Short Hills NJ, US
Michael Yellin - Upper Montclair NJ, US
Steven Fischkoff - Short Hills NJ, US
Jeffrey Weber - Los Angeles CA, US

C12Q 1/68

435006000

The invention provides methods for predicting responsiveness of a subject to therapy with a CTLA-4 blocking agent. The methods involve assaying for at least one CTLA-4 polymorphism in the subject and predicting responsiveness of the subject to therapy with a CTLA-4 blocking agent based on presence or absence of a CTLA-4 polymorphic allele in the subject. The methods can further comprise selecting a treatment regimen with a CTLA-4 blocking agent in a subject based upon presence or absence of a CTLA-4 polymorphic allele in the subject. The methods can further comprise administering a CTLA-4 blocking agent to the subject according to the selected treatment regimen. Kits comprising a CTLA-4 blocking agent and means for assaying one or more CTLA-4 polymorphisms, optionally including a vaccine, are also provided.

7611702, Nov 3, 2009

Nov 8, 2006

11/557835

Steven Fischkoff - Short Hills NJ, US
Israel Lowy - Dobbs Ferry NY, US
Michael Yellin - Montclair NJ, US
James Chung-Yin Yang - Silver Spring MD, US

Medarex, Inc. - Princeton NJ

A61K 39/395, A61K 38/16, C07K 16/28, C07K 16/46

4241301, 4241341, 5303871, 5303873

The present invention provides methods for treating adverse events related to immunotherapy. More specifically, the present invention provides methods for treating the enterocolitis associated with anti-CTLA-4 antibody immunotherapy.

2009021, Aug 27, 2009

Apr 25, 2006

11/918272

Steven Fischkoff - Short Hills NJ, US
Michael Yellin - Montclair NJ, US

MEDAREX - Princeton NJ

A61K 39/395

4241381, 4241421, 4241431

Methods for treating lymphomas characterized by expression of CD30 using anti-CD30 antibodies and steroids in combination are disclosed.